[Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis].

Abstract

A comparison of the antiemetic effects of (H) and (M) was carried out by randomized control study in gynecologic cancer patients receiving CDDP (35-110 mg/m2). Metoclopramide was given at a dosage of 2 mg/kg (H) or 1 mg/kg (M), intravenously, 30 minutes before and 2.5 hours, 5.0 hours, and 7.5 hours following chemotherapy. Treatment with (H) resulted in 3.3 episodes of vomiting (range 0-5) whereas the episodes of vomiting noted with (M) were 3.4 (range 1-5). In patients receiving CDDP (H) or (M) dosage of metoclopramide gives similar antiemetic protection.

• Authors: H Dozono, K Ohmi
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 13 Issue 3 Pt 1 Pg. 454-7 (Mar 1986) ISSN: 0385-0684 [Print] Japan
• PMID: 3954370 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Metoclopramide
• Cisplatin

Topics

• Aged
• Cisplatin (adverse effects)
• Drug Administration Schedule
• Female
• Humans
• Metoclopramide (administration & dosage)
• Middle Aged
• Nausea (drug therapy)
• Ovarian Neoplasms (drug therapy)
• Random Allocation
• Uterine Neoplasms (drug therapy)
• Vomiting (drug therapy)